CVS Health said it entered into an Underwriting Agreement on December 3, 2024 with Barclays Capital Inc., Citigroup Global Markets Inc. and Goldman Sachs & Co. LLC as representatives of the underwriters.

8-KOther EventsFiled Dec 5, 2024Period of report Dec 3, 2024Summary published (UTC) Oct 25, 2026

Key points

AI summary

CVS Health said it entered into an Underwriting Agreement on December 3, 2024 with Barclays Capital Inc., Citigroup Global Markets Inc. and Goldman Sachs & Co. LLC as representatives of the underwriters.
The company said it agreed to issue and sell 7.000% Series A Junior Subordinated Notes due 2055 to the underwriters, in an aggregate principal amount of $2,250,000,000.
The company also said it agreed to issue and sell 6.750% Series B Junior Subordinated Notes due 2054 to the underwriters, in an aggregate principal amount of $750,000,000.
The company said the closing of the sale of the Notes is expected on December 10, 2024, and that net proceeds after underwriting discounts and estimated offering expenses are expected to be about $2,963,075,700.

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Underwriting agreement with 3 underwriters

CVS Health said it entered into an Underwriting Agreement on December 3, 2024 with Barclays Capital Inc., Citigroup Global Markets Inc. and Goldman Sachs & Co. LLC as representatives of the underwriters.

Source · Based on the filing body and exhibits

Series A Junior Subordinated Notes terms

The company said it agreed to issue and sell 7.000% Series A Junior Subordinated Notes due 2055 to the underwriters, in an aggregate principal amount of $2,250,000,000.

Source · Based on the filing body and exhibits

Series B Junior Subordinated Notes terms

The company also said it agreed to issue and sell 6.750% Series B Junior Subordinated Notes due 2054 to the underwriters, in an aggregate principal amount of $750,000,000.

Source · Based on the filing body and exhibits

Expected closing date and net proceeds

The company said the closing of the sale of the Notes is expected on December 10, 2024, and that net proceeds after underwriting discounts and estimated offering expenses are expected to be about $2,963,075,700.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.